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ung cancer is the most common cause of mortality due to cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer. 1 Despite potential benefits of surgical resection, patients with the same pathologic stage of disease display marked variability in recurrence and survival. Moreover, the outcome after treatment in many cases has been very dismal. The evolution of each individual case results from the particular combination of characteristics of the patient and the tumor. The poor results attained so far are at least in part, related to the high potential of NSCLC to metastasize as well as to locally recur. These events, in turn, are not easy to predict. Better knowledge of the molecular biology of NSCLC might improve the capability to predict the outcome for any individual patient, which in turn would be helpful to define subgroups of patients for adjuvant treatment with either conventional cytotoxic chemotherapy or novel targeted agents. 2 Tumor aggressiveness is conditioned by different biological factors that regulate, among other things, the cell cycle, angiogenesis, cellular adhesion, and apoptosis. Some of these factors have been evaluated to understand the way they operate and interact, and to find helpful tools to identify patients with bad prognoses. Results have been so far inconclusive. [2] [3] [4] [5] The objective of the present study was to evaluate several histopathologic variables and a panel of molecular markers in patients with stage I NSCLC after complete tumor resection to assess their prognostic value. The molecular markers analyzed in this study encompass various biological mechanisms of tumor growth and metastases development. For a deeper look into this complex process, we also analyzed clinical data, histopathologic observations, and molecular markers with the aid of a multivariate test.
Materials and Methods

Patients
Fifty-three patients with stage I NSCLC treated between January 1985 and December 1999 were identified from the files of the Hospital de Rehabilitació n Respiratoria "María Ferrer" of Buenos Aires, Argentina. Mediastinal lymph node resection was performed in all tumor staging. Inclusion criteria for entry into the present study were pathologic stage IA (T1N0M0) and IB (T2N0M0) according to the revised International System for Staging Lung Cancer, 6 radical surgery, nonneoadjuvant therapy, follow-up of at least 6 months, and available tissue samples for immunohistochemical study.
Histopathologic Studies
Two pathologists (C.P. and B.N.) independently reviewed all the histologic slides from the 53 patients in a blind fashion following the World Health Organization 1999 classification. 1 Discrepancies were solved by joint review. Pathologic features recorded included the following: tumor cell type, degree of differentiation (well, moderate, and poor), tumor size (T1, up to 3 cm; T2, Ͼ 3 cm), and mitosis number in 10 high-power fields (1, up to 5; 2, 6 to 10; 3, Ͼ 10). We also analyzed lymphatic vessel invasion (0, absent; 1, present), vascular invasion, or tumor emboli (0, absent; 1, present), tumor necrosis (0, absent; 1, Ͻ 10%; 2, 11 to 50%; and 3, Ͼ 50%), and visceral pleural invasion (0, absent; 1, present). The intensity of angiogenesis was assessed by microvessel density (microvessel defined as capillaries and small venules) in five tumor areas of maximal vascularization (400 ϫ) identified by antibody staining to factor VIII and routine hematoxylin-eosin staining; the result was displayed as the mean of the five measurements and stratified by median.
Immunohistochemistry
For immunohistochemical demonstration of the antibodies outlined in Table 1 , formalin-fixed paraffin-embedded tissue specimens were cut into 4-m sections and mounted on positivecharged slides, deparaffined, and rehydrated through xylene and alcohol. After quenching the endogenous peroxidase activity with 0.3% H 2 O 2 in methanol, the slides were placed in plastic Coplin jars containing citrate buffer solution (1:10 Citra plus; Biogenex; San Ramon, CA). The jars were then placed in a pressure cooker and heated in a microwave oven for 20 min (10 min at high power and 10 min in 80% power) to unmask antigen. After cooling for 10 min, the slides were incubated with blocking serum for 5 min. The slides were then incubated with primary antibody for 1 h at room temperature, followed by phosphate-buffered saline solution washes and incubated with biotinylated secondary antibody (UltraTech HRP; Streptavidin-Biotin Universal Detection System Immunotech; Marseille, France). After that, the slides were washed with the aid of phosphate-buffered saline solution and incubated with Streptavidin-enzyme reagent for 10 min. Revelation was achieved with 3-3Јdi-amino bencidina, and visualization was aided by counterstaining with hematoxylin.
The MIB-1 and Bcl-2 stain was graded as 0 (no staining), 1 (1 to 33%), 2 (34 to 66%), and 3 (67 to 100%). The CD44 was graded as 0 (no staining), 1 (Ͻ 10% staining), 2 (up to 50%), 3 (Ͼ 50%); grades 0 or 1 were considered negative. E-cadherin was graded as 0 (Ͻ 10%), 1 (Ͻ 50%), and 2 (Ͼ 50%). The vascular endothelial growth factor (VEGF) expression in Ͼ 5% of neoplastic cells was considered positive. p53 protein stain was graded as 0 (no staining), 1 (up to 10%), 2 (11 to 50%), and 3 (Ͼ 50%), with grades 0 and 1 being considered negative.
Statistical Analysis
We chose to evaluate the time to relapse considering either local recurrence or distant metastasis. Cancer recurrence was defined as the period ranging from the date of surgery to the date when relapse was diagnosed. An observation was censored at the last follow-up if the patient was alive or the patient had died of a cause other than NSCLC. Statistical analysis was performed using the SPSS software system (SPSS for Windows Version 10.0; SPSS; Chicago, IL). The 2 test and Fisher exact test were used to analyze the associations between categorical clinical, pathologic, and molecular variables. Specific time to recurrence curves were plotted using the Kaplan-Meier method, while the log-rank test was used to assess the statistical significance of differences between groups. Multivariate analyses were performed using stepwise Cox proportional hazards model to identify independent prognostic factors. The criterion for significance was p Ͻ 0.05.
Results
Patient Characteristics
There were 8 women (15%) and 45 men (85%) with a mean Ϯ SD age at diagnosis of 60.8 Ϯ 8.7 years (range, 42 to 81 years). Fifty patients (94%) were smokers. Forty-six patients underwent lobectomy, 6 patients underwent pneumonectomy, and only 1 patient underwent segmentectomy. Eighteen patients (34%) had stage IA, and 35 patients (66%) had stage IB.
The median follow-up period was 59 months (range, 9 to 168 months). The overall survival was 52.8% (28 of 54 patients), and the median diseasefree time was 55 months (range, 5 to 168 months). Twenty-five patients died: 12 deaths for unrelated cause and 13 deaths for progression of disease. Twenty-eight percent (15 of 53 patients) had recurrent disease: 2 patients (4%) had local progression, and 13 patients (24%) had distant metastasis. 
Histopathology
The histologic typing showed 28 adenocarcinomas (53%), 23 squamous cell carcinomas (SCCs) [43%], and 2 large cell carcinomas (4%). We included the last two types in the SCC group for histopathologic and immunohistochemical analysis (except differentiation).
The tumor size average was 4.40 cm (SD, 1.87; range, 0.8 to 12.5 cm); 62% were Ͼ 3.0 cm. With respect to mitotic counting, 64% had more than five mitoses in 10 high-power fields (grades 2 and 3); 54.7% lacked necrosis or it was focal, 58% had lymphatic vascular invasion, and 21% had visceral pleura invasion, while only 17% presented vascular invasion; 37.3% of tumors were well differentiated, 33.3% were moderate, and 29.4% were poor. We found significant differences between SCC and adenocarcinoma (Table 2) in mitotic counting (p ϭ 0.001) and lymphatic permeation (p ϭ 0.01). Table 2 lists the frequency of positivity, (weak and strong expression combined) of the various biological markers studied. The MIB-1 immunostaining failed in three cases; 44% was in grade 1, 40% was in grade 2, and 16% was in grade 3. The immunostaining for p53 was nuclear and was expressed in 43.4% of cases, whereas staining for Bcl-2 protein was cytoplasmatic and was expressed in 30.1% of cases. The Ecadherin and CD44 expression were cytoplasmatic with weakly border stain in 86.8% and 50.9%, respectively. The VEGF expression was cytoplasmatic in 81% of cases. The SCCs showed higher proliferation (MIB-1 grades 2 and 3) [p ϭ 0.001], Bcl-2 expression (p ϭ 0.038), and CD44 expression (p ϭ 0.019) than adenocarcinomas. 
Immunohistochemistry
Association Between Histopathologic and Biological Factors
Tumor size appeared directly associated with the presence of necrosis (p ϭ 0.01) and visceral pleura invasion (p ϭ 0.02), while the mitosis count was directly associated with necrosis (p ϭ 0.02), MIB-1 expression (p ϭ 0.003), and p53 expression (p ϭ Table 3 shows that mitosis count and Bcl-2 expression were significantly associated with recurrence. Tables 4, 5 list the results of univariate analysis for the prognostic significance of each histopathologic factor and molecular marker in relation to time to recurrence. The log-rank test showed that mitosis count, necrosis, MIB-1, and Bcl-2 were predictive factors for relapse. All of them were associated with increased relapse and a shorter time to recurrence. Median time to recurrence was 16 months for necrosis more extensive than 50% (Fig 1) , and 96 months for tumors with more than five mitoses (Fig 2) . For MIB-1 expression grade 3, the median time to recurrence was 17 months (Fig 3) , and for Bcl-2-positive tumors was 60 months (Fig 4) . Stage subcategories (IA and IB) and other factors did not appear to affect the outcome (Kaplan-Meier curves not shown).
Prognostic Value of Histopathologic Factors and Molecular Markers
Multivariate analysis using the Cox proportional hazards regression model was performed to determine independent prognostic factors of lung cancer relapse. Analyzed factors included tumor size, mitosis, lymphatic vascular invasion, and visceral pleura invasion (Table 6 ), and MIB-1, p53, Bcl-2, CD44, E-cadherin, and VEGF ( Table 7) . As a result, mitosis count, Bcl-2 expression, and grade 3 of Mib-1 emerged as independent prognostic factors of recurrence.
When data were stratified according to histopathologic type, MIB-1 (p ϭ 0.0027), mitosis (p ϭ 0.0314), and Bcl-2 (p ϭ 0.00001) were associated with increased relapse and a shorter time to recurrence on stage I patients with adenocarcinomas, while Bcl-2 (p ϭ 0.0104) appeared predictive for stage I patients with SCCs. Multivariate analysis showed that MIB-1 grade 3 (p ϭ 0.0294) and Bcl-2 grade 3 (p ϭ 0.0301) were significant independent prognostic factors of recurrence on patients with adenocarcinomas, but not for patients with SCCs.
When data were separated according to subcategories IA and IB, it was found that mitosis (p ϭ 0.0070) and Bcl-2 expression (p ϭ 0.0073) were associated with poor time to recurrence among stage IA patients, while MIB-1 (p ϭ 0.0052) and Bcl-2 (p ϭ 0.0006) appeared predictive in stage IB patients. Multivariate analysis showed that MIB-1 grade 3 (p ϭ 0.0059) and Bcl-2 grade 3 (p ϭ 0.0185) were independent prognostic factor of recurrence in stage IB patients but not for stage IA patients.
Discussion
The clinical observation that patients carrying stage I NSCLC present different clinical courses and may respond differently to similar treatments remains yet to be fully understood. In this study, we investigated both histopathologic variables and molecular markers in a group of 53 patients with stage I NSCLC.
In our series, 65% of tumors had high mitosis count and 58% had moderate or high proliferative activity (MIB-1 expression). Univariate and multivariate analysis revealed significant association between prognosis and both mitosis count and MIB-1 expression: the patients with high mitosis count and high grade of MIB-1 expression presented shorter time to recurrence than patients with low proliferative tumors. Moreover, mitosis count and MIB-1 expression were particularly increased among patients carrying SCCs rather than on those carrying adenocarcinomas. However, they appeared as significant prognostic factors for patients with adenocarcinomas but not for patients with SCCs. High proliferative tumors presented less differentiation, reflecting that differentiation arrests tumor growth. Mitotic count is the most common histopathologic factor used to assess proliferative activity of a tumor and is frequently employed for classification and predicting prognosis. Cell proliferation can also be evaluated through the detection of Ki 67, a nuclear antigen that can be determined using the MIB-1 antibody that recognizes both native as well as recombinant fragments of the Ki 67 molecules expressed in proliferating cells. 7 Several investigators have studied the role of MIB-1 expression in predicting the outcome of patients with lung cancer after surgery with opposite results. Tanaka et al 4 found no significant correlation between proliferative activity, other histopathologic factors, and survival time, while Ishida et al 8 found a significantly poor prognosis on patients carrying adenocarcinomas with high Ki 67 expression.
We also found direct association between necrosis, tumor size, and mitosis count, and an inverse relationship with differentiation: the tumor growth rate was higher in less differentiated tumors. In our series, patients with tumors with no or focal necrosis had a significantly longer time to recurrence than those with grade 2 or 3 necrosis. This finding could not be confirmed in multivariate analysis. One reason to explain this failure is that necrosis is considered in the literature to be a passive and vaguely regulated event frequently triggered by external injurious agents. 9 Tumor size, visceral pleural invasion, and stratification into IA and IB groups did not show any prognostic value.
We found Bcl-2-protein expression with statistically significant association with histology and clinical outcome in 30% of the tumors of this series. These results are in agreement with previous reports 10, 11 showing that SCCs express Bcl-2 more frequently than adenocarcinomas. We also found in multivariate analysis that Bcl-2 protein expression emerged as a significant marker of poor long-term prognosis; only 7 of 37 patients with Bcl-2-negative tumors had recurrence. Moreover, Bcl-2 also appeared as a prognostic factor on univariate analysis regardless of the histopathologic type and stage subcategories. Bcl-2 is a human proto-oncogene located on chromosome 18 that encodes inhibitors of apoptosis and can act as oncogene by reducing the rate of cell death. Its product is an integral membrane protein called Bcl-2 located in the membranes of the endoplasmic reticulum, nuclear envelope, and in the outer membranes of the mitochondria. Apoptosis, a type of cell death genetically determined and characterized with morphologic and biochemical criteria, can be initiated by internal or external signals. 12, 13 Bcl-2 may inhibit a central step in the death pathway of apoptotic cells or protect an essential cellular constituent that is the target of apoptotic programs. 13 The value of Bcl-2 in predicting the outcome of a patient with NCSLC is controversial. While several studies showed that Bcl-2 expression is associated with favorable prognosis, others found no association or even negative results. 5,14 -18 A consistent feature in many studies is the positive association between apoptosis and proliferation. This is probably due to the fact that most cells undergo apoptosis primarily in the G1 phase of cycling cells. In theory, since Bcl-2 inhibits apoptosis, its overexpression should favor the malignant process resulting in a poor outcome. Paradoxically, several studies 5,14 -18 have associated Bcl-2 expression in NSCLC with a good prognosis as mentioned previously.
Forty-three percent of our cases expressed p53 protein, especially in moderately and poor differentiated and high mitosis count tumors. Since p53 is a tumor suppressor gene that can induce temporary growth arrest and DNA repair or apoptosis in response to potentially oncogenic cellular stress such as DNA damage, our results might be related to the fact that impairment of cell growth control results in uncontrolled cell proliferation. We did not find prognostic value in p53 expression. The relationship between p53 expression and prognosis remains unclear. While some studies indicate that it is a significant factor of poor prognosis among NSCLC patients, others did not find any impact in clinical outcome. 8, 14, 17, 18 We also found a significant association between CD44 and Bcl-2 expression; both of them are more frequently expressed in SCC than in adenocarcinomas. CD44 is a primary cell surface receptor for hyaluronan, a proteoglycan involved in cell-cell and cell-matrix adhesive interactions, which can be found in abundance in the extracellular matrix. There is substantial evidence that these adhesive interactions play a vital role in tumor genesis, progression, and metastasis. 19 -21 In previous reports, 22,23 the expression of CD44 was associated with node lymphatic metastasis. We failed to find association of CD44 expression with prognosis. This may result from the fact that only T1-2N0M0 stage cases were considered. Cellular adhesion inhibits proliferation. If CD44 expression in the surface of the neoplastic cells is lacking, the sensitivity to apoptosis increases. 24 This fact could explain the correlation found between Bcl-2 and CD44. It is worthwhile to recall that E-cadherin (also named L-CAM) is the most important member of the Cadherin cell adhesion molecules group, which is a fundamental determinant of tissue organization in developing and adult organisms. 19 Other authors 25, 26 found inverse correlation between E-cadherin expression and invasion in several tumors. In our series, E-cadherin expression was present in 87% of tumors with no relation with patient's outcome, probably because it is associated with limited disease. 25 Tumor cells produce angiogenic factors that induce the formation of new blood vessels from the preexisting vasculature. Angiogenesis is not an isolated event but a cascade of processes emanating from microvascular endothelial cells, including a role for VEFG, a potent endothelial cell specific mitogen and angiogenic factor. 27 VEFG is produced by several types of tumors, where it as been shown to influence both tumor neovascularization and tumor dissemination. While angiogenesis and high expression of VEGF have been found to be associated with poor prognosis in NSCLC by some authors, 28, 29 other studies showed that VEGF had no prognostic value. 30 We found correlation between microvessel count and VEGF immunoreactivity, but none of these factors had a relevant association with prognosis.
The prognosis for patients with cancer is divided into tumor-, patient-, and environment-related factors. Better understanding of the biology of tumors should provide useful information to predict clinical outcome and individualize treatment; however, the prognostic role of histopathologic and biological factors is hard to determine because of tumor heterogeneity. This is especially true in lung neoplasm and could be based on the existence of different mechanisms of tumor progression. For example, we observed that SCCs showed high proliferative activity, strong Bcl-2, and CD44 immunoreactivity, while adenocarcinomas had frequent lymphatic vascular invasion. However, only strong Bcl-2 expression presented predictive values for recurrence regardless of the histopathologic type.
Conclusion
In the present study, we found that mitosis count and MIB-1 expression were independent prognostic factors in patients with stage I NSCLC. They had significant value to predict recurrence, reflecting the aggressiveness of high-rate proliferative tumors, and suggesting the convenience to include these factors in pathologic reports.
We also found poor prognosis in patients with positive Bcl-2 tumors, which appeared as an independent prognostic factor regardless of the histopathologic type, probably because Bcl-2 expression promotes uncontrolled cell growth. These observations do contribute to clarify the controversial value of Bcl-2 as a predictive factor in NSCLC stage I outcome.
We believe that these histopathologic factors and molecular markers have potential prognostic value to estimate outcome after resection of stage I NSCLC and should be taken into account. They might facilitate the development of rational postresection treatment strategies based on the estimated risk of recurrence; however, they must be investigated in depth before promoting their use in individual cases.
